F-1: Optimi Health Corp. Files F-1 for Nasdaq Listing

Sentiment:

F-1 Registration Statement 5 September 2025 9:20 PM

Optimi Health Corp., a Canadian GMP-compliant psychedelic drug manufacturer, files an F-1 registration statement for a U.S. IPO and Nasdaq Capital Market listing, aiming to expand into U.S. and Israeli markets.

Delay expectedU.S. market entry for psilocybin and MDMA is currently restricted due to their Schedule I classification and is dependent on FDA approval and DEA rescheduling, which may not occur on a timely basis or at all.We anticipate needing additional funds to continue preparing for U.S. market entry after the next 12 months, as we do not expect to gain market entry within that timeframe.The FDA's rejection of Lykos Therapeutics' application for MDMA-assisted therapy for PTSD on August 9, 2024, indicates potential delays and high regulatory hurdles for similar therapies in the U.S. market.

Capital raiseWe are undertaking an initial public offering (IPO) of common shares in the United States, expecting net proceeds of approximately US$ million (or US$ million if the over-allotment option is fully exercised).We issued 3,450 unsecured convertible debentures at C$1,000 per debenture for gross proceeds of C$3,450,000 on July 24, 2025.Historically, we have relied upon the sale of equity securities and loans for cash required for operations and development.We intend to finance future requirements through a combination of debt and/or equity issuances.

Worse than expectedWe have a history of recurring operating losses and an accumulated deficit of C$25,939,066 (US$19,044,836) as of June 30, 2025.The financial statements explicitly state 'substantial doubt about its ability to continue as a going concern' without additional financing.Our cash and cash equivalents are low at C$88,533 (US$65,003) as of June 30, 2025, indicating limited liquidity despite recent capital raises.

Summary

We are a Canadian GMP-compliant pharmaceutical drug manufacturer specializing in MDMA and psilocybin derived from botanical sources.
We operate two 10,000 sq. ft. production facilities in Princeton, British Columbia, holding a Drug Establishment Licence (DEL), Dealers Licence (DL), and Precursor Licence from Health Canada.
Our products are currently available in Australia for prescription use (MDMA for PTSD, psilocybin for TRD) under the Authorised Prescribers Scheme, and in Canada via the Special Access Program (SAP).
Our psilocybin product is in Phase 2b clinical trials in Canada (conducted by third parties), and our MDMA product is in Phase 2 clinical trials in Israel (conducted by third parties).
U.S. market entry is a planned target but is currently restricted due to the Schedule I classification of psilocybin and MDMA, requiring FDA approval and DEA rescheduling.
We reported a net loss of C$2,362,664 (US$1,734,704) for the nine months ended June 30, 2025, and C$6,035,859 (US$4,431,615) for the fiscal year ended September 30, 2024.
We have an accumulated deficit of C$25,939,066 (US$19,044,836) as of June 30, 2025.
Revenue increased to C$490,330 (US$360,007) for the nine months ended June 30, 2025, from C$331,991 in the prior year period, driven by drug product commercialization.
Cost of sales decreased to C$94,227 (US$69,183) for the nine months ended June 30, 2025, from C$176,660, due to a shift from nutraceutical products to higher-margin drug products.
Expenses decreased to C$3,670,347 (US$2,694,823) for the nine months ended June 30, 2025, from C$4,593,468, reflecting cost-cutting efforts.
Directors forgave C$903,951 (US$663,694) in accounts payable in the nine months ended June 30, 2025.
We are winding down our nutraceutical business to focus on pharmaceutical-grade manufacturing.
We have applied to list our common shares on the Nasdaq Capital Market under the trading symbol OPTH, with approval being a condition of closing the offering.
Our Board approved a reverse share split (1-for-[ ]) to meet Nasdaq minimum share price requirements, anticipated to be effective immediately prior to uplisting.

Sentiment

Score: 3

Explanation: We are operating in a high-growth, innovative sector with significant regulatory hurdles and a history of substantial losses, raising going concern doubts. While we have made progress in licensing and initial market entry in Australia, our financial health is weak, and future success is highly dependent on uncertain regulatory changes and successful capital raises. The current offering and recent convertible debt provide some liquidity, but the path to sustained profitability remains uncertain and highly dependent on external factors and successful execution of ambitious growth strategies.

Positives

We are a GMP-compliant pharmaceutical drug manufacturer with Health Canada licenses (DEL, DL, Precursor Licence) for controlled substances.
Our operations are vertically integrated with two 10,000 sq. ft. production facilities, allowing for rapid scaling and quality control.
We have an early-mover advantage with MDMA and psilocybin products available by prescription in Australia for PTSD and TRD, and via the Special Access Program in Canada.
We are actively supplying products to third-party clinical trials in Canada (psilocybin Phase 2b) and Israel (MDMA Phase 2).
Our FDA Establishment Identifier (FEI) number and U.S. Agent appointment position us for future U.S. market entry.
We have established strategic partnerships with organizations like Mind Medicine Australia and Tel Aviv University.
Cost-cutting measures have led to reduced expenses and debt forgiveness by directors (C$903,951) in the recent nine-month period.
Revenue from drug products and licensing increased to C$490,330 for the nine months ended June 30, 2025, from C$331,991 in the prior year.
We have production capacity scalable to 500,000 or more MDMA doses and 1,000,000 5mg psilocybin doses annually.

Negatives

We have a history of operating losses and an accumulated deficit of C$25,939,066 (US$19,044,836) as of June 30, 2025.
There is substantial doubt about our ability to continue as a going concern without securing additional financing.
U.S. market entry is currently restricted due to the Schedule I classification of psilocybin and MDMA, requiring uncertain FDA approval and DEA rescheduling.
We rely on third parties to conduct clinical trials and some aspects of research and preclinical testing, which introduces external dependencies.
We do not currently own any patents or have pending patent applications related to our MDMA and botanical psilocybin products, relying on proprietary know-how and trade secrets.
We face inherent product liability and regulatory action risks, including potential product recalls.
The industry is new and highly competitive, with some competitors being more established and having greater resources.
Negative public perception or controversy surrounding psychedelic substances could adversely affect our business.
Global operations expose us to foreign currency risks and potential supply chain interruptions for raw materials and API inputs.
Our Nasdaq listing is contingent on approval, and we intend to rely on foreign private issuer exemptions from certain corporate governance standards, which may offer less protection to shareholders.

Risks

We face various controlled substance regulatory compliance risks, including uncertainty as to future regulations and potential material adverse repercussions for violations.
Our ability to obtain and maintain necessary licenses (Dealers Licence, Precursor Licence, Drug Establishment Licence) is critical and not assured.
Changes in U.S. legislative and regulatory policies, including tariffs and rescheduling delays, could materially adversely impact us.
We face inherent risks related to product liability claims, regulatory action, and product recalls.
Our products may be subject to regulatory quotas, such as the DEA's quota system, which could limit procurement or manufacturing capacity.
The psychedelic industry and market are relatively new, with no guarantee of sustainable revenue streams or business expansion.
We have a limited operating history and may not be able to effectively manage our growth.
We have a history of operating losses, and there is no assurance of achieving profitability or raising additional financing on acceptable terms, raising substantial doubt about our ability to continue as a going concern.
Developing and manufacturing biopharmaceutical products is expensive and time-consuming, with uncertain outcomes, and our product candidates are in preclinical or clinical development with third parties.
Broad market access in the U.S. for MDMA and psilocybin is dependent on DEA rescheduling from Schedule I, which is uncertain and may be delayed.
If we are unable to maintain or obtain sufficient intellectual property protection (currently no patents), competitors could commercialize similar products.
Third parties may claim infringement, misappropriation, or violation of their intellectual property rights.
We may not be able to obtain patent term extensions in key markets, shortening our exclusive marketing period.
Failure to protect the confidentiality of our trade secrets could materially adversely affect the value of our products.
The expense and uncertainty of litigation may prevent us from enforcing our intellectual property rights.
There has been no prior market for our common shares on a U.S. national securities exchange, and an active and liquid market may fail to develop.
As a foreign private issuer, we intend to rely on exemptions from certain Nasdaq corporate governance standards, which may afford less protection to shareholders.
We will be subject to ongoing public reporting requirements that are less rigorous than for non-emerging growth companies.
It may be difficult to enforce judgments or bring actions outside the United States against us and our directors.
Purchasers in this offering will experience immediate and substantial dilution in the book value of their investment.
Future financings may lead to further dilution for shareholders.
Our management has broad discretion over the use of offering proceeds, which may not always align with shareholder expectations.
We do not currently intend to pay dividends, meaning returns depend on share price appreciation.
We may be subject to securities litigation, which is expensive and distracting.
We may not be able to satisfy Nasdaq listing requirements or maintain our listing.
We may be deemed a controlled foreign corporation or a passive foreign investment company (PFIC) for U.S. federal income tax purposes, leading to adverse tax consequences for U.S. Holders.
Negative results from clinical trials or studies conducted by third parties could adversely affect our business.
We face potential shortages in raw materials, including psychedelic mushrooms and API inputs.
Reliance on third-party manufacturers and suppliers creates risks related to production delays and quality control.
Strategic collaborations, licenses, and other arrangements may not be successful or yield anticipated benefits.
Our success depends on the performance of our management and employees, and potential conflicts of interest may arise.
Natural disasters, public health crises, political crises, and other catastrophic events could adversely affect our business.
Our financial statements are prepared under IFRS, which differs from U.S. GAAP, potentially affecting comparability.
Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
The availability of adequate third-party payer coverage and reimbursement for newly approved drugs is uncertain.
Market opportunities for our product candidates may be smaller than we believe.
Challenges in effectively executing growth strategies and managing risks associated with expanding international operations.
Cyberattacks or other failures in our telecommunications or information technology systems could disrupt business operations.

Future Outlook

We intend to use the net proceeds from this offering for scaling production and distribution of our products in current markets, preparing for additional market entry to Israel and the United States, sales growth, and general working capital. We anticipate needing additional funds for U.S. market entry after the next 12 months. We expect margin expansion through economies of scale in procurement, higher batch yields, automation of processes, fixed-cost dilution as production scales, ongoing process optimization under GMP frameworks, and efficiencies from our GMP and DEL licensing infrastructure and on-site analytical laboratory.

Management Comments

We are dedicated to becoming a global leader in the psychedelic pharmaceutical sector.
Our research initiatives focus on optimizing extraction efficiency, improving formulation stability and ensuring scalable manufacturing techniques that align with future market expansion plans.
Unlike most companies in the psychedelic sector that remain in clinical or pre-commercial phases, we are currently supplying regulated medicines under prescription in certain markets.
We believe we are strategically positioned to supply pharmaceutical-grade MDMA and psilocybin capsules to regulated treatment providers in the United States immediately following rescheduling and FDA approval events.
Our facility operates with a mindset of continuous improvement, ensuring that quality systems are not only compliant today but built to support future scale-up and international regulatory requirements.

Industry Context

We operate in a nascent, highly regulated, and increasingly competitive psychedelic pharmaceutical industry. While the sector faces challenges such as stigma, legal uncertainty, and physician hesitancy, there is expanding regulatory openness in certain jurisdictions. We differentiate ourselves by being a GMP-compliant manufacturer with products already available by prescription in Australia, setting us apart from many competitors still in clinical or pre-commercial stages. The U.S. market is identified as a strategically critical and commercially significant future demand center, contingent on regulatory rescheduling and FDA approvals, which are complex and uncertain processes.

Comparison to Industry Standards

Unlike most companies in the psychedelic sector, such as Compass Pathways, Atai Life Sciences, and MindMed, which are primarily in clinical or pre-commercial phases, we are currently supplying regulated medicines under prescription in Australia.
Our GMP-compliant manufacturing facilities and possession of a Drug Establishment Licence (DEL) provide a durable competitive advantage in terms of cost efficiency, quality assurance, and regulatory readiness compared to other psychedelic manufacturers.
The FDA's rejection of Lykos Therapeutics' MDMA-assisted therapy application for PTSD on August 9, 2024, highlights the high regulatory hurdles in the industry, which we acknowledge as a significant risk for U.S. market entry.
Our current production capacity, capable of supporting up to 100,000 PTSD patients with MDMA therapy and 200,000 TRD patients with psilocybin therapy annually, positions us for early-stage market entry and scaling compared to many pre-revenue clinical-stage peers.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Independent Registered Public Accounting Firm	Smythe LLP	Davidson & Company LLP	November 6, 2024	Smythe LLP resigned, and Davidson & Company LLP was appointed by the Board of Directors on the recommendation of the Audit Committee.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Composition	We intend to rely on exemptions from certain Nasdaq corporate governance standards applicable to U.S. domestic issuers due to our foreign private issuer status, including not having a majority of independent directors.	Upon Nasdaq listing	May afford less protection to holders of our common shares than they would enjoy if we complied fully with Nasdaq corporate governance listing standards.
Board Meetings	We do not intend to hold regular scheduled meetings that independent directors exclusively attend.	Upon Nasdaq listing	May afford less protection to holders of our common shares.
Committee Structure	We do not intend to have a nomination committee. We do not intend to have a compensation committee comprised solely of independent directors.	Upon Nasdaq listing	May afford less protection to holders of our common shares.
Director Nomination Process	We do not intend to have director nominees selected or recommended for the Board's selection by independent directors, nor adopt a formal written charter or board resolution addressing the nominations process.	Upon Nasdaq listing	May afford less protection to holders of our common shares.
Shareholder Meetings	We do not intend to follow the requirement for holding an annual meeting of shareholders no later than one year after the end of the fiscal year-end. Instead, we will follow home country practice, requiring a general meeting at least once every calendar year, not later than 15 months after the preceding annual general meeting.	Upon Nasdaq listing	May provide less frequent shareholder engagement compared to U.S. domestic issuers.
Shareholder Quorum	We do not intend to follow Nasdaq requirements for shareholder quorum. Instead, we will follow home country practice, requiring a quorum of two persons representing at least 5% of issued voting shares.	Upon Nasdaq listing	May make it easier to achieve quorum for shareholder meetings.
Audit Committee Independence	We are relying on the phase-in rules of Nasdaq with respect to the independence of our audit committee, which may not be fully independent for up to one year following this offering.	Upon Nasdaq listing	Could affect the effectiveness of our audit committee and the perception of our corporate governance by investors during the phase-in period.
Shareholder Approval for Security Issuances	We do not intend to follow Nasdaq requirements for shareholder approval prior to certain security issuances (e.g., acquisitions, equity-based compensation, change of control, non-public offerings), instead complying with Canadian Securities Exchange policies.	Upon Nasdaq listing	Shareholders may have less direct control over certain corporate actions involving security issuances compared to U.S. domestic issuers.
Compensation Recovery Policy	We have adopted a compensation recovery (clawback) policy compliant with Nasdaq listing rules as required by the Dodd-Frank Act.	Prior to Nasdaq listing	Enhances corporate accountability and aligns with regulatory best practices.
Code of Business Conduct and Ethics	The Code of Business Conduct and Ethics was amended.	July 18, 2025	Reflects updated internal standards and compliance requirements.

Legal Proceedings

We are currently not party to any material legal or arbitration proceedings that may have, or have had in the recent past, significant effects on our financial position or profitability.

Related Party Transactions

John James Wilson (Director and Non-Executive Chair) and Dane Stevens (CEO, CMO, Director) have participated in private placement transactions and convertible debenture issuances.
Catcher Investments Ltd. (controlled by John James Wilson) provided a C$1,000,000 loan on August 4, 2023, and subscribed for 3,000 convertible debentures (C$3,000,000) on July 24, 2025.
Cathay Visions Enterprises Ltd. (controlled by Dane Stevens) subscribed for units in private placements on February 23, 2024 (1,000,000 units), May 10, 2024 (666,667 units), August 15, 2024 (333,333 units), and January 24, 2025 (733,334 units), and subscribed for 450 convertible debentures (C$450,000) on July 24, 2025.
We have an industrial ground lease agreement with BC Green Pharmaceuticals Inc., where Bryan Safarik (COO, Director) and Jacob Safarik (Interim CFO, Director) serve as directors/officers and own equity interests (Bryan ~13.7%, Jacob ~14.2%). The lease was amended on July 1, 2025, extending the term to June 30, 2030, with renewal options.
Certain directors forgave C$903,951 in accounts payable during the nine months ended June 30, 2025.

Stakeholder Impact

Shareholders: Potential for significant dilution from the IPO and future capital raises. Risk of share price volatility due to new market listing and industry uncertainty. Less protection due to foreign private issuer exemptions from Nasdaq corporate governance standards.
Employees: Continued employment and potential for equity-based compensation under the Equity Plan. Risk of job insecurity if the company fails to achieve profitability or secure additional funding.
Customers (Patients/Prescribers): Continued supply of MDMA and psilocybin products in regulated markets (Australia, Canada SAP). Potential for expanded access if U.S. market entry is successful.
Suppliers/Creditors: Our ability to meet financial obligations is dependent on future profitability and financing. Debt forgiveness by directors indicates some financial strain.
Regulatory Bodies: Our operations are subject to strict compliance with Health Canada, FDA, DEA, and Australian TGA regulations, requiring ongoing adherence and potential for increased scrutiny.

Next Steps

Complete the U.S. initial public offering and list common shares on the Nasdaq Capital Market.
Effect a reverse share split to meet Nasdaq minimum share price requirements.
Scale production and distribution of products in current markets (Canada, Australia).
Expand into additional markets, specifically Israel and the United States.
Continue investing in research and development for drug formulations.
Strengthen regulatory compliance.
Collect real-world evidence (RWE) and patient-reported outcomes (PROs) for Australian regulatory submissions.
Further collaborations with healthcare providers and government agencies to advocate for safe and effective psychedelic-assisted therapies.
Prepare for full abbreviated new drug application (ANDA) filings to access broader generic market channels post-exclusivity in the U.S.
Develop and validate laboratory methodologies according to USP or EP standards, validate instrumentation and software, staff the laboratory, and complete QMS requirements for GMP to generate complete Certificates of Analysis (COAs) in-house.
Advance scale-up of the encapsulation program by validating an automatic encapsulator.
Submit similar documentation to the FDA for the Drug Master File (DMF) in 2026.

Key Dates

Date	Description
May 27, 2020	Company incorporated under the Business Corporations Act (British Columbia) as 1251418 B.C. Ltd.
July 6, 2020	Completed the First Private Placement, raising C$1,000,000.
July 23, 2020	Entered into an industrial ground lease agreement with BC Green Pharmaceuticals Inc. for the Princeton Facilities.
August 17, 2020	Changed name to Optimi Health Corp.
September 11, 2020	Closed the Special Warrant Private Placement, issuing 17,963,005 Special Warrants for gross proceeds of C$4,490,751.
September 16, 2020	Applied for trademark protection for Optimi and Optimi Health in Canada and the United States.
October 9, 2020	Equity Incentive Plan adopted and approved by shareholders.
January 12, 2021	Special Warrants automatically deemed exercised into SW Units. Trademark protection for Optimi and Optimi Health granted in Canada.
February 25, 2021	Closed initial public offering in Canada, raising C$20,700,000; common shares and IPO Warrants commenced trading on the CSE.
April 1, 2021	Effective date of arrangement with Dane Stevens as Chief Executive Officer and Chief Marketing Officer.
April 1, 2021	Effective date of employment agreement with Jacob Safarik as Chief Financial Officer.
April 1, 2021	Effective date of employment agreement with Bryan Safarik as Chief Operating Officer.
April 1, 2021	Obtained the symbol OPTHF to commence trading on the OTCPINK market in the United States.
April 6, 2021	Commenced trading on the Frankfurt Stock Exchange under the symbol 8BN.
July 2, 2021	Employment agreements with Jacob Safarik and Bryan Safarik dated.
September 1, 2021	Industrial ground lease agreement with BC Green Pharmaceuticals Inc. amended and restated.
June 27, 2022	Princeton Facilities considered substantially complete and depreciation commenced on the plant.
October 7, 2022	Issued 5,692,308 units at C$0.325 per unit for gross proceeds of C$1,850,000.
February 28, 2023	Signed purchase orders with Mind Medicine Australia Limited and entered into a supply agreement with KMT Pharmaceuticals Pty Ltd.
August 1, 2023	Employment agreements with Jacob Safarik and Bryan Safarik amended.
August 4, 2023	Entered into a loan agreement with Catcher Investments Ltd. for C$1,000,000, issuing 100,000 common share purchase warrants. Maturity Date: August 4, 2026.
August 29, 2023	Entered into a loan agreement with two independent third-party lenders for C$1,000,000, issuing 100,000 common share purchase warrants. Maturity Date: August 29, 2026.
November 1, 2023	Entered into a loan agreement with Kerris Holdings Ltd. for C$1,000,000, issuing 100,000 common share purchase warrants. Original Maturity Date: April 30, 2025.
November 3, 2023	Entered into a supply agreement with Sunshine Earth Labs Ltd.
December 2023	Granted Precursor Licence by Health Canada.
February 23, 2024	Issued 1,850,033 units at C$0.30 per unit for gross proceeds of C$555,009.
March 22, 2024	Entered into an international natural psilocybin supply agreement with Matai Medical Research Institute (New Zealand). Entered into a Collaborative Research Agreement with Kwantlen Polytechnic University.
April 2024	Completed validated GMP production of 5mg natural psilocybin extract capsules with a Certificate of Analysis (COA).
May 2024	Received a Drug Establishment Licence (DEL) from Health Canada. Completed validated GMP production of MDMA 40mg & 60mg capsules with a COA. Received an export permit for the first international shipment of MDMA to Israel. Entered into a Phase II clinical trial supply agreement for natural psilocybin extract with ATMA CENA Healthcare Solutions.
May 10, 2024	Issued 1,333,334 units at C$0.30 per unit for gross proceeds of C$400,000.
May 29, 2024	Issued 1,816,633 units at C$0.30 per unit for gross proceeds of C$544,990.
June 2024	Health Canada issued three export permits to supply Australia's Authorised Prescribers Scheme. Secured an import certificate from Mind Med Australia for 160 doses of MDMA and psilocybin.
August 2024	Completed the first shipment of MDMA to Mind Medicine Australia for PTSD treatment. First patients dosed in Australia's Authorised Prescribers Scheme with MDMA capsules.
September 2024	Announced supplier partnership with Tel Aviv University.
November 6, 2024	Smythe LLP resigned as independent registered public accounting firm; Davidson & Company LLP appointed.
December 2024	Completed the second shipment of MDMA to Mind Medicine Australia. Completed initial shipment to Matai Medical Research Institute (New Zealand).
January 24, 2025	Issued 1,316,668 units at C$0.30 per unit for gross proceeds of C$395,000. Settled debt of C$98,126.25 by issuing 458,145 common shares.
April 2025	Completed the third shipment of 1,000 MDMA capsules to Australia. Received FDA Establishment Identifier (FEI) number. Engaged mdi Consultants, Inc. as U.S. agent.
May 2025	Received import permit from the TGA and export permit from Health Canada for 1,000 capsules of 5mg natural psilocybin extract.
July 1, 2025	Industrial ground lease agreement with BC Green Pharmaceuticals Inc. further amended to extend the term to June 30, 2030, with three additional 5-year renewal options.
July 16, 2025	Loan Agreement Amendment No. 1 with Kerris Holdings Ltd. extended the maturity date from April 30, 2025, to April 30, 2026.
July 18, 2025	Amended the Code of Business Conduct and Ethics.
July 24, 2025	Issued 3,450 unsecured convertible debentures for gross proceeds of C$3,450,000. Issued 400,000 common shares purchase warrants as consideration for a loan amendment with Kerris Holdings Ltd.
September 3, 2025	Commercially launched natural psilocybin capsules in Australia, now being prescribed to patients with TRD under the Authorised Prescribers Scheme.
September 5, 2025	F-1 Registration Statement filed with the U.S. Securities and Exchange Commission.

Recommendation

hold

We are at a critical juncture, transitioning from early-stage operations to a more mature pharmaceutical model with a U.S. IPO and Nasdaq listing. While we possess strong competitive strengths in our GMP-compliant manufacturing and early market access in Australia, significant financial risks persist, including a history of losses and going concern doubts. Our future success hinges on navigating complex regulatory pathways, particularly for the lucrative U.S. market, and securing substantial additional financing. The current offering and recent convertible debt provide some liquidity, but the path to sustained profitability remains uncertain and highly dependent on external factors and successful execution of ambitious growth strategies. Investors should monitor regulatory developments and financial performance closely.

Keywords

Psychedelics, MDMA, Psilocybin, Pharmaceutical, Health Canada, GMP, Nasdaq IPO, Drug Development, Mental Health, PTSD, TRD, Controlled Substances, Biotech, Canada, Australia, Israel, US Market, F-1 Filing, Reverse Share Split

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.